What is Keystone Heart?
Keystone Heart is an enterprise focused on advancing cardiac technologies. While specific details of its product pipeline are proprietary, the company's engagement in major funding rounds suggests a focus on developing and scaling innovative solutions within the cardiovascular medical device industry. The substantial capital raised indicates a commitment to significant research and development, clinical trials, and market penetration strategies, positioning Keystone Heart as a notable player in the competitive healthcare technology landscape.
How much funding has Keystone Heart raised?
Keystone Heart has raised a total of $14M across 1 funding round:
Series B
$14M
Series B (2014): $14M with participation from OrbiMed
Key Investors in Keystone Heart
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. Their investment approach reflects a comprehensive understanding of healthcare innovation cycles and market dynamics, supporting companies at various stages of development.
What's next for Keystone Heart?
With a recent major strategic investment, Keystone Heart is poised for accelerated growth and product development. The enterprise-level funding suggests a transition towards later-stage commercialization or significant expansion of its operational capacity. Future endeavors will likely involve scaling manufacturing, expanding clinical study reach, and potentially entering new markets. The strategic nature of the recent financing implies a partnership aimed at leveraging synergistic expertise or market access, which will be critical for navigating the complex regulatory and commercial pathways in the medical device sector.
See full Keystone Heart company page
